相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
S. S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
Peera Hemarajata et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility
L. Silvia Munoz-Price et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges
Marissa D. Malchione et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae
William R. Wilson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model
Safa S. Almarzoky Abuhussain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
Kenneth S. Thomson et al.
ANTIBIOTICS-BASEL (2019)
Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model
Lindsay M. Avery et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Carbapenemase-Producing Organisms: A Global Scourge
Robert A. Bonomo et al.
CLINICAL INFECTIOUS DISEASES (2018)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
Helio S. Soder et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype
Edward R. Bevan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
Latania K. Logan et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature
Ryan K. Shields et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States
S. M. Bartsch et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
The Role of Epidemic Resistance Plasmids and International High-Risk Clones in the Spread of Multidrug-Resistant Enterobacteriaceae
Amy J. Mathers et al.
CLINICAL MICROBIOLOGY REVIEWS (2015)
CTX-M-type β-lactamases: A successful story of antibiotic resistance
Marco Maria D'Andrea et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2013)
Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections
D. Ben-David et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Carbapenems: Past, Present, and Future
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
Neil Gupta et al.
CLINICAL INFECTIOUS DISEASES (2011)
Pharmacokinetics and pharmacodynamics of antimicrobials
G. L. Drusano
CLINICAL INFECTIOUS DISEASES (2007)
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations
D Andes et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model
D Maglio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid
WA Craig
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
Animal model pharmacokinetics and pharmacodynamics: a critical review
D Andes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
分享论文
